Genetic profile of second primary tumors and recurrences in head and neck squamous cell carcinomas

Head and Neck

Volumn 34, Issue 6, 2012, Pages 830-839

  Gutiérrez, Virginia Franco ^a,b   Marcos, César Álvarez ^a,b   Llorente, José Luis ^a,b   Guervõs, Marta Alonso ^b   Iglesias, Francisco Domínguez ^c   Tamargo, Luis Argüelles ^b   Hermsen, Mario ^a,b  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

^c HOSPITAL VALLE DEL NALÓN   (Spain)

Author keywords

genetic alterations; head and neck squamous cell carcinoma; MLPA; second primary tumors; tumor recurrences

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ONCOPROTEIN; PROTEIN BCL 2; PROTEIN CCND1; PROTEIN EMS1; PROTEIN TYROSINE PHOSPHATASE 1B; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COPY NUMBER VARIATION; CROSS-SECTIONAL STUDY; FEMALE; FOLLOW UP; GAIN OF FUNCTION MUTATION; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; MALE; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; PRIORITY JOURNAL; PROGNOSIS; SECOND CANCER; TUMOR GROWTH;

ADULT; AGED; BCL-X PROTEIN; CARCINOMA, SQUAMOUS CELL; CATHEPSIN B; CELL CYCLE PROTEINS; CORTACTIN; CROSS-SECTIONAL STUDIES; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; INTERLEUKIN-18; LAMIN TYPE A; LARYNGEAL NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; NUCLEIC ACID AMPLIFICATION TECHNIQUES; ONCOGENE PROTEINS; PHARYNGEAL NEOPLASMS; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 1; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84861329504     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21824     Document Type: Article

References (29)

1. Sikora AG, Toniolo P, DeLacure MD,. The changing demographics of head and neck squamous cell carcinoma in the United States. Laryngoscope 2004; 114: 1915-1923.
2. González-García R, Naval-Gías L, Román-Romero L, Sastre-Pérez J, Rodríguez-Campo FJ,. Local recurrences and second primary tumors from squamous cell carcinoma of the oral cavity: a retrospective analytic study of 500 patients. Head Neck 2009; 31: 1168-1180.
3. Álvarez Marcos C, Llorente Pendás JL, Franco Gutiérrez V, et al. Tumour recurrence in squamous head and neck cancer. [Article in Spanish] Acta Otorrinolaringol Esp 2007; 58: 156-163.
4. Brenner B, Marshak G, Sulkes A, Rakowsky E,. Prognosis of patients with recurrent laryngeal carcinoma. Head Neck 2001; 23: 531-535.
5. Álvarez Marcos CA, Llorente Pendás JL, Franco Gutiérrez V, et al. Second primary tumors in head and neck cancer. [Article in Spanish] Acta Otorrinolaringol Esp 2006; 57: 462-466.
6. Dooghe IJ, De Vos M, Van Cauwenberge PB,. Multiple primary malignant tumors in patients with head and neck cancer: results of a prospective study and future perspectives. Laryngoscope 1998; 108: 250-256.
7. Rennemo E, Zätterström U, Boysen M,. Impact of second primary tumors on survival in head and neck cancer: an analysis of 2,063 cases. Laryngoscope 2008; 118: 1350-1356.
8. Álvarez Marcos CA, Llorente Pendás JL, Franco Gutiérrez V, et al. Distant metastases in head and neck cancer. [Article in Spanish] Acta Otorrinolaringol Esp 2006; 57: 369-372.
9. Braakhuis BJ, Tabor MP, Leemans CR, van der Waal I, Snow GB, Brakenhoff RH,. Second primary tumors and field cancerization in oral and oropharyngeal cancer: molecular techniques provide new insights and definitions. Head Neck 2002; 24: 198-206.
10. Álvarez Marcos C, Alonso Guervõs M, Rodríguez Prado N, et al. Genetic model of transformation and neoplastic progression in laryngeal epithelium. Head Neck 2010 (Epub ahead of print).
11. Cabanillas R, Llorente JL,. The Stem Cell Network model: clinical implications in cancer. Eur Arch Otorhinolaryngol 2009; 266: 161-170.
12. Wong LY, Wei WI, Lam LK, Yuen AP,. Salvage of recurrent head and neck squamous cell carcinoma after primary curative surgery. Head Neck 2003; 25: 953-959.
13. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G,. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 2002; 30: e57.
14. Almadori G, Bussu F, Cadoni G, et al. Multistep laryngeal carcinogenesis helps our understanding of the field of cancerisation phenomenon: a review. Eur J Cancer 2004; 40: 2383-2388.
15. Hermsen M, Alonso Guervõs M, Meijer G, et al. Chromosomal changes in relation to clinical outcome in larynx and pharynx squamous cell carcinoma. Cell Oncol 2005; 27: 191-198.
16. Tremmel SC, Götte K, Popp S, et al. Intratumoral genomic heterogeneity in advanced head and neck cancer detected by comparative genomic hybridization. Cancer Genet Cytogenet 2003; 144: 165-174.
17. Singh B, Stoffel A, Gogineni S, et al. Amplification of the 3q26.3 locus is associated with progression to invasive cancer and is a negative prognostic factor in head and neck squamous cell carcinomas. Am J Pathol 2002; 161: 365-371.
18. Califano J, van der Riet P, Westra W, et al. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 1996; 56: 2488-2492.
19. Sasiadek MM, Stembalska-Kozlowska A, Smigiel R, Ramsey D, Kayademir T, Blin N,. Impairment of MLH1 and CDKN2A in oncogenesis of laryngeal cancer. Br J Cancer 2004; 90: 1594-1599.
20. Smigiel R, Stembalska-Kozlowska A, Mirghomizadeh F, et al. Correlation among loss of heterozygosity, promoter methylation and protein expression of MLH1 in larynx cancer. Oncol Rep 2004; 11: 707-710.
21. Lee JW, Kim MR, Soung YH, et al. Mutational analysis of the CASP6 gene in colorectal and gastric carcinomas. APMIS 2006; 114: 646-650.
22. Rosin MP, Cheng X, Poh C, et al. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res 2000; 6: 357-362.
23. Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH,. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res 2003; 63: 1727-1730.
24. Schoop RA, Kooistra K, Baatenburg De Jong RJ, Noteborn MH,. Bcl-xL inhibits p53- but not apoptin-induced apoptosis in head and neck squamous cell carcinoma cell line. Int J Cancer 2004; 109: 38-42.
25. Capaccio P, Pruneri G, Carboni N, et al. Cyclin D1 expression is predictive of occult metastases in head and neck cancer patients with clinically negative cervical lymph nodes. Head Neck 2000; 22: 234-240.
26. Nogueira CP, Dolan RW, Gooey J, et al. Inactivation of p53 and amplification of cyclin D1 correlate with clinical outcome in head and neck cancer. Laryngoscope 1998; 108: 345-350.
27. Rodrigo JP, García LA, Ramos S, Lazo PS, Suárez C,. EMS1 gene amplification correlates with poor prognosis in squamous cell carcinomas of the head and neck. Clin Cancer Res 2000; 6: 3177-3182.
28. Guervõs MA, Marcos CA, Hermsen M, Nuño AS, Suárez C, Llorente JL,. Deletions of N33, STK11 and TP53 are involved in the development of lymph node metastasis in larynx and pharynx carcinomas. Cell Oncol 2007; 29: 327-334.
29. Kim MM, Califano JA,. Molecular pathology of head-and-neck cancer. Int J Cancer 2004; 112: 545-553.